通过靶向肿瘤相关巨噬细胞的嵌合受体工程化溶瘤病毒重振内源性抗肿瘤免疫
Rejuvenating endogenous antitumor immunity via a chimeric receptor-engineered oncolytic virus targeting tumor-associated macrophages.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:A promising future in cancer immunotherapy: Oncolytic viruses.
A promising future in cancer immunotherapy: Oncolytic viruses.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
除传统疗法外,基于免疫治疗的方法也日益受到关注。免疫疗法已成为治疗肿瘤的一种选择,具有更高特异性并可能改善疗效,可增强或调节免疫系统,从而配合靶向病毒治疗。溶瘤病毒疗法是一类溶瘤免疫治疗,近几十年来因具有多种优势而在癌症治疗中受到广泛研究。随着对癌细胞生物学及肿瘤发生机制的认识不断深入,也随着对条件复制型溶瘤病毒及其破坏肿瘤细胞功能的了解增加,目前已能够将这一策略用于恶性肿瘤治疗。根据溶瘤病毒临床试验取得的成果,有理由期待这类治疗在癌症治疗中发挥更核心的作用。未来,将溶瘤病毒与标准癌症治疗及其他免疫疗法联合,有望获得更佳疗效。
Alongside the conventional methods, attention has been drawn to the use of immunotherapy-based methods for cancer treatment. Immunotherapy has developed as a therapeutic option that can be more specific with better outcomes in tumor treatment. It can boost or regulate the immune system behind the targeted virotherapy. Virotherapy is a kind of oncolytic immunotherapy that investigated broadly in cancer treatment in recent decades, due to its several advantages.
According to recent advance in the field of understanding cancer cell biology and its occurrence, as well as increasing the knowledge about conditionally replicating oncolytic viruses and their destructive function in the tumor cells, nowadays, it is possible to apply this strategy in the treatment of malignancies.
Relying on achievements in clinical trials of oncolytic viruses, we can certainly expect that this therapeutic perception can play a more central role in cancer treatment. In cancer treatment, combination therapy using oncolytic viruses alongside standard cancer treatment methods and other immunotherapy-based treatments can expect more promising results in the future.
MEMBER ACCOUNT
登录成功会直接打开下一页。